A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting Conditions

NCT04553978 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: WD-1603

Sponsor

Hong Kong WD Pharmaceutical Co., Limited